Ngr. Jr. Med. Sc. vol-2, issue-8 (Aug-2026) pp-257-260

ISSN: 3139-5309 (Online)

Nexus Global Research Journal of Medical Sciences

Journal Homepage: https://nexusglobalresearch.com/index.php/ngrjms

Review Article:

Early Detection and Diagnosis: Implications for Better Kidney Outcomes

[1]Ozoemena Chimaoge Covenant, Nnodim Johnkennedy[2]*,

[1]Department of Chemical Pathology, Faculty of Medical Laboratory Science, Federal University Otuoke, Bayelsa State, Nigeria.

[2]Department of Medical Laboratory Science, Imo State University, Owerri, Imo State, Nigeria.

ABSTRACT:

Kidney disease is an escalating global health problem that impacts millions of people and is a leading cause of morbidity, mortality and health care costs. Of particular worry is chronic kidney disease (CKD) because it may be unnoticed for years before clinical illness becomes evident. By the time patients approach with symptoms such as fatigue, oedema, changes in urination or other signs of severe disease, considerable and potentially permanent loss of kidney function may have already taken place. Therefore, early detection and precise diagnosis are critical techniques for avoiding or delaying disease progression and enhancing kidney outcomes in the long run. Routine examination with estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (ACR), blood pressure monitoring, blood glucose assessment, and suitable imaging can identify patients at greater risk. Early detection also allows for the identification of modifiable risk factors, initiation of renoprotective medications, treatment of underlying diseases and monitoring of disease development. This article will address the significance of early detection and diagnosis of kidney illness, the main laboratory and clinical procedures used in screening, the consequences of delayed diagnosis, and efforts to improve renal outcomes by timely intervention. Better knowledge, risk-based screening, laboratory capacity and integration of renal assessment into primary health care could greatly enhance early detection and minimise the burden of kidney disease.

Keyword: Kidney disease, chronic kidney disease, early diagnosis, diagnosis, renal outcomes, eGFR, albuminuria, kidney health

Citation: Ugwo, K. C., Eberendu, & Izuchukwu, F. (2026). Prevalence and pattern of short-term complications of diabetes mellitus in South-Eastern Nigeria: A multicenter cross-sectional study. *Nexus Global Research Journal of Medical Sciences, 2*(5), 127–137.

INTRODUCTION

The kidneys conduct important physiologic tasks, including excretion of metabolic waste products, regulation of fluid and electrolyte balance, acid-base homeostasis, regulation of blood pressure, and generation of hormones involved in erythropoiesis and mineral metabolism. Impairment of kidney function can consequently have effects beyond the renal system, and may contribute to cardiovascular disease, anaemia, metabolic abnormalities, bone and mineral diseases, and premature death [1].

Chronic kidney disease (CKD) is defined as abnormalities in kidney structure or function, present for >3 months, with health concerns. The chief causes and risk factors for CKD are diabetes mellitus and hypertension, but glomerular illnesses, hereditary disorders, recurrent urinary tract blockage, nephrotoxic exposures, infections, and other conditions may also be involved. The increasing prevalence of diabetes, hypertension, obesity, ageing populations and other non-communicable diseases has amplified the global burden of kidney disease [2].

One major problem in managing renal disease is that early CKD is typically asymptomatic. Patients may develop overt symptoms once kidney function has been significantly impaired. Therefore, screening for kidney disease based on symptoms alone may lead to late presentation and missed opportunities for care[3]. Early detection enables the identification of at-risk persons, confirmation of disease, determination of severity, investigation of possible causes, and institution of suitable treatment before considerable kidney damage develops [4].

IMPORTANCE OF EARLY DETECTION IS IMPORTANT

Early identification is particularly critical, as kidney disease often progresses. Uncontrolled hypertension, hyperglycaemia, proteinuria, smoking, obesity and nephrotoxic chemicals are risk factors that, with ongoing exposure, can exacerbate kidney injury. Catching a sickness early provides you with an opportunity to fix these issues before the disease worsens [5].

A primary benefit of early diagnosis is the opportunity to

***Corresponding Author:** Ozoemena Chimaoge Covenant

Received: 10 July 2026 | **Accepted:** 06 August 2026 | **Published:** 25 August 2026

Copyright © 2026 The Author(s): This work is licensed under a Creative Commons Attribution- Non-Commercial-No Derivatives 4.0 (CC BY-NC-ND 4.0) International License

avoid or postpone progression to renal failure. Appropriate control of blood pressure, management of glycaemia in those with diabetes, decrease of albuminuria, lifestyle change and use of evidence-based renoprotective medicine can slow the rate of deterioration of kidney function in suitable patients. An early diagnosis also allows for ongoing monitoring, so clinicians can see how kidney function is changing and adjust medication accordingly [6].

Furthermore, renal illness is strongly related with cardiovascular morbidity. Patients with CKD have an elevated risk of cardiovascular events and mortality. Thus, early identification of CKD may be a chance not only to preserve renal function but also to identify patients who require comprehensive cardiovascular risk reduction [7].

LABORATORY STRATEGIES FOR EARLY DETECTION OF KIDNEY DISEASE

Laboratory tests are still the mainstay of identification and diagnosis of renal disease. Serum creatinine is one of the most routinely utilised kidney function indicators. Serum creatinine alone, however, may not be a sufficient marker of early renal impairment because its concentration can be altered by muscle mass, age, sex, food and other factors [8].

It is for this reason that serum creatinine is frequently utilised in equations to predict glomerular filtration rate. The estimated glomerular filtration rate is a more therapeutically meaningful definition of renal function and enables classification of CKD by severity. Serial examination of eGFR is particularly useful as changes over time can be more informative than a single measurement [9].

Another important aspect in the early diagnosis of renal illness is the determination of urinary albumin. Albuminuria may be an early sign of glomerular injury, especially in people with diabetes and hypertension. The urine albumin/creatinine ratio is a practical method of assessing urinary albumin excretion while minimising the impact of fluctuation in urine concentration. The combination of eGFR and albuminuria accurately represents the existence and severity of CKD and the risk of its development [10][11].

Other studies may be necessary depending on the clinical setting. These may include urinalysis, urine microscopy, serum electrolytes, blood urea nitrogen, complete blood count, lipid profile, glucose or glycated haemoglobin, autoimmune screens, serology and renal imaging. Kidney ultrasound can be particularly useful in determining renal size, structural abnormalities, blockage and other anatomical aspects.

THE IMPACT OF DELAYED DIAGNOSIS

Delayed diagnosis can have major effects for patients and health care systems. Failure to recognise CKD may mean missing possibly reversible or adjustable causes. Chronic hypertension and hyperglycaemia can hasten kidney deterioration in vulnerable individuals. Inappropriate use of nephrotoxic drugs may cause further deterioration of kidney function in a similar manner [12].

Late presentation may potentially limit the therapeutic options. Patients diagnosed at advanced stages may require professional nephrology treatment, preparation for kidney replacement therapy, dialysis or kidney transplantation. These therapies are costly, resource-intensive and may have a major impact on patients' quality of life [13].

In addition, advanced CKD can cause problems such as anaemia, metabolic acidosis, electrolyte abnormalities, mineral and bone dysfunction, fluid overload, and cardiovascular disease. The faster you find them, the better your chances of identifying and treating these problems before they get worse [14].

HIGH RISK GROUPS FOR DISEASE REQUIRING SCREENING

Universal screening for renal disease may not always be feasible in resource limited settings. Therefore, risk-based screening may be an efficient technique for early detection. CKD risk is markedly elevated in people with diabetes and hypertension and they should be prioritised. Other populations that may benefit from focused screening are those with cardiovascular disease, obesity, a family history of kidney disease, prior episodes of acute kidney injury, recurrent urinary tract disorders, systemic diseases with renal involvement, and those who have been exposed to potentially nephrotoxic agents [15].

Another major factor is age. Kidney function fluctuates with age however aberrant findings should not be dismissed to age alone without proper testing. Periodic measurement of renal function in those known to be at risk may allow detection of clinically important abnormalities earlier [16].

EARLY INTERVENTION IMPROVES KIDNEY OUTCOMES

The value of early diagnosis rests ultimately on the availability of appropriate therapies. Without effective follow-up and treatment, identification of CKD will have limited impact on outcomes. Therefore, early diagnosis should be combined with complete illness management.

Controlling blood pressure is an important part of

protecting the kidneys. Hypertensive patients with CKD should be treated individually to reach adequate blood pressure targets. Good control of diabetes can also lower the risk of renal problems. Pharmacological treatment can be complemented with lifestyle therapies like adequate nutrition, physical exercise, weight control, smoking cessation and reduction of excessive salt intake.

Renoprotective drugs have also changed the management of CKD in appropriate patient categories. Depending on the underlying condition and clinical features, drugs that reduce intraglomerular pressure, albuminuria, or other causes of kidney injury may slow the progression of disease. Early identification of these therapies can be considered prior to the development of advanced renal impairment [17].

POINT-OF-CARE AND EMERGING TECHNOLOGIES

Advances in technology are creating new chances for early identification of kidney disease. Point-of-care testing can help to rapidly identify creatinine, glucose and urine problems in primary healthcare and community settings. Such approaches may be particularly useful in scenarios where there is restricted access to centralised laboratories [18].

Digital health technologies can also be used for renal disease surveillance. Electronic medical records, clinical decision-support systems, mobile health platforms and automated risk assessment tools may aid healthcare workers in identifying individuals needing renal evaluation. But technological solutions should be validated and integrated into existing health care systems as such. Emerging biomarkers may further improve early diagnosis by identifying kidney injury before significant declines in current measurements of filtration. Biomarkers of tubular injury, inflammation, fibrosis, and glomerular injury are under investigation to determine their potential for diagnostic and prognostic purposes. Many are still purely research tools but the ongoing biomarker research may enhance the ability to identify high-risk patients for progression [19].

IMPLICATIONS IN LOW-RESOURCE SETTINGS

Early diagnosis of kidney illness is especially critical in poor and middle-income countries where there may be difficulties for patients to access healthcare and professional nephrology facilities may be scarce. In such conditions, relatively simple investigations such as blood pressure measurement, serum creatinine/eGFR, urinalysis, urine albumin assessment, and blood glucose testing may have significant clinical significance.

A pragmatic approach might be to add screening for renal disease to current programs for diabetes and hypertension. Training primary healthcare staff to identify persons at elevated risk and develop referral pathways for patients with aberrant findings is feasible. Improvement of laboratory facilities and availability of required reagents and equipment on a regular basis are of paramount importance.

Prevention efforts could also include public education. We should encourage people to take appropriate screening tests when they feel well especially when they have known risk factors. The increased understanding of silent progression of renal disease may induce earlier healthcare-seeking behaviour [20].

CONCLUSION

Early detection and precise diagnosis of renal problems is key to better kidney outcomes. The development of kidney disease is often asymptomatic, and if clinicians rely only on clinical signs, it may result in delayed diagnosis and missed opportunities for prevention. The practical basis for diagnosis of renal problems and assessment of disease severity include measurement of eGFR, urine albumin excretion, blood pressure, blood glucose, urinalysis and suitable imaging.

Early diagnosis offers advantages in addition to renal function maintenance. Early detection allows clinicians to treat underlying causes, mitigate cardiovascular risk factors, minimise complications, optimise drug use, and prepare appropriately for advanced disease as necessary. Regular screening and systematic monitoring in high-risk populations may significantly decrease the chance of undiscovered illness development.

Ultimately, improving kidney outcomes will need a move from mostly reactive therapy of advanced renal disease to proactive identification and intervention. Enhancing primary healthcare screening, laboratory diagnostic capacity, healthcare-worker awareness, patient education, and access to evidence-based renoprotective therapies can make early kidney disease diagnosis a viable and successful part of modern healthcare. Early diagnosis should therefore be considered not only as a diagnostic goal but as an important step toward preventing renal failure, reducing cardiovascular disease, improving quality of life and decreasing the overall burden of kidney disease.

REFERENCES:

1.Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O'Callaghan, C.A., Lasserson, D.S. and Hobbs, F.D.R. (2016). Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS ONE, 11(7), e0158765.

2.Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A.Y.M. and Yang, C.W. (2013). Chronic kidney disease: global dimension and perspectives. The Lancet, 382(9888), pp.260–272.

3.Mills, K.T., Xu, Y., Zhang, W., Bundy, J.D., Chen, C.S., Kelly, T.N., Chen, J. and He, J. (2015). A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney International, 88(5), pp.950–957.

4.Levin, A. and Stevens, P.E. (2011). Early detection of CKD: the benefits, limitations and effects on prognosis. Nature Reviews Nephrology, 7, pp.446–457.

5.Stevens, P.E. and Levin, A. (2013). Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline. Annals of Internal Medicine, 158(11), pp.825–830.

6.Tangri, N., Grams, M.E., Levey, A.S., Coresh, J., Appel, L.J., Astor, B.C., Chodick, G., Collins, A.J., Djurdjev, O., Edwards, D. et al. (2016). Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA, 315(2), pp.164–174.

7.Coca, S.G., Ismail-Beigi, F., Haq, N., Krumholz, H.M. and Parikh, C.R. (2011). Role of biomarkers for the prediction of renal and cardiovascular outcomes in patients with diabetes. Diabetes Care, 34(Suppl. 2), pp.S371–S378.

8.Fassett, R.G., Venuthurupalli, S.K., Gobe, G.C., Coombes, J.S., Cooper, M.A. and Hoy, W.E. (2011). Biomarkers in chronic kidney disease: a review. Kidney International, 80(8), pp.806–821.

9.Levey, A.S., Coresh, J., Balk, E., Kausz, A.T., Levin, A., Steffes, M.W., Hogg, R.J., Perrone, R.D., Madias, N.E. and Eknoyan, G. (2003). National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine, 139(2), pp.137–147.

10.Inker, L.A., Eneanya, N.D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D.C., Doria, A., Estrella, M.M., Froissart, M. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), pp.1737–1749.

11.Levey, A.S., Inker, L.A. and Coresh, J. (2015). GFR estimation: from physiology to public health. American Journal of Kidney Diseases, 66(4), pp.531–538.

12.Shlipak, M.G., Matsushita, K., Ärnlöv, J., Inker, L.A., Katz, R., Polkinghorne, K.R., Rothenbacher, D., Sarnak, M.J., Astor, B.C., Coresh, J. and Gansevoort, R.T. (2013). Cystatin C versus creatinine in determining risk based on kidney function. New England Journal of Medicine, 369(10), pp.932–943.

13.Hallan, S.I., Matsushita, K., Sang, Y., Mahmoodi, B.K., Black, C., Ishani, A., Kleefstra, N., Naimark, D., Fox, C.S. and Coresh, J. (2012). Age and association of kidney measures with mortality and end-stage renal disease. JAMA, 308(22), pp.2349–2360.

14. Excel, D. K., Chisom, O. A., Chinyere, E. T. D., Nwadikor, U. U., Nneka, O. I., & Ihuarulam, O. C. (2025). Microbial Analysis of Three-Leaf Yam (Dioscorea dumetorum): Microbiological Quality and Spoilage Dynamics During Storage. *IOASD Journal of Medical and Pharmaceutical Sciences, 2*(4), 161-164.

15.Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.A., Fogo, A.B., Fox, C.S., Gansevoort, R.T., Heerspink, H.J.L., Jardine, M. et al. (2017). Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 390(10105), pp.1888–1917.

16.Shlipak, M.G., Tummalapalli, S.L., Boulware, L.E., Grams, M.E., Ix, J.H., Jha, V., Kengne, A.P., Madero, M., Mihaylova, B., Tangri, N (2021). The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney International, 99(1), pp.34–47.

17.Coresh, J., Selvin, E., Stevens, L.A., Manzi, J., Kusek, J.W., Eggers, P., Van Lente, F. and Levey, A.S. (2007). Prevalence of chronic kidney disease in the United States. JAMA, 298(17), pp.2038–2047.

18.Pena, M.J., Stenvinkel, P., Kretzler, M., Adu, D., Agarwal, S.K., Coresh, J., Feldman, H.I., Fogo, A.B., Gansevoort, R.T., Harris, D.C. (2017). Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. Kidney International Supplements, 7(2), pp.107–113.

19.Coca, S.G., De Lemos, J.A., Parikh, C.R. (2010). The cardiorenal connection in heart failure and chronic kidney disease. Clinical Journal of the American Society of Nephrology, 5(11), pp.2077–2084.

20.Shlipak, M.G., Day, E.C. and Shastri, S. (2018). Cystatin C and kidney function: an update. Clinical Chemistry and Laboratory Medicine, 56(6), pp.896–906.